Zobrazeno 1 - 2
of 2
pro vyhledávání: '"María T Soler-Monsó"'
Autor:
Andrea Vethencourt, Eva M Trinidad, Anna Petit, María T Soler-Monsó, Clara Gómez Aleza, Ander Urruticochea, Amparo García-Tejedor, Anna Gumà Martinez, Veronica Obadia, Silvia Vazquez, Rafael Villanueva, Adela Fernánez, Monica Cejuela, Sabela Recalde Penabad, Agostina Stradella, Miguel Gil-Gil, Sonia Pernas, Eva Gonzalez-Suarez, Catalina Falo
Publikováno v:
Cancer Research. 82:P2-08
Background: Most breast cancers (BC) exhibit low immune infiltration and are unresponsive to immunotherapy. Inhibitors of the Receptor Activator of NFkB (RANK) pathway, such as denosumab, used for the treatment of bone metastasis, have been shown to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::347906a2aa7c8134ef274e70efcfb32a
https://doi.org/10.1158/1538-7445.sabcs21-p2-08-10
https://doi.org/10.1158/1538-7445.sabcs21-p2-08-10
RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer
Autor:
Marina Ciscar, Eva M Trinidad, Gema Perez‐Chacon, Mansour Alsaleem, Maria Jimenez, Maria J Jimenez‐Santos, Hector Perez‐Montoyo, Adrian Sanz‐Moreno, Andrea Vethencourt, Michael Toss, Anna Petit, Maria T Soler‐Monso, Victor Lopez, Jorge Gomez‐Miragaya, Clara Gomez‐Aleza, Lacey E Dobrolecki, Michael T Lewis, Alejandra Bruna, Silvana Mouron, Miguel Quintela‐Fandino, Fatima Al‐Shahrour, Antonio Martinez‐Aranda, Angels Sierra, Andrew R Green, Emad Rakha, Eva Gonzalez‐Suarez
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 4, Pp 1-12 (2023)
Abstract Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL p
Externí odkaz:
https://doaj.org/article/1a7e932a6a184ce6a384d4a58e43a0be